Proleukin
Total Payments
$32.1M
Transactions
1,105
Doctors
406
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5.1M | 51 | 0 |
| 2021 | $4.1M | 51 | 23 |
| 2020 | $4.9M | 74 | 52 |
| 2019 | $3.2M | 110 | 77 |
| 2018 | $8.9M | 299 | 139 |
| 2017 | $6.0M | 520 | 273 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $32.0M | 373 | 99.7% |
| Grant | $41,500 | 11 | 0.1% |
| Consulting Fee | $40,067 | 21 | 0.1% |
| Food and Beverage | $21,861 | 684 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $750.00 | 1 | 0.0% |
| Education | $104.17 | 15 | 0.0% |
Payments by Type
Research
$32.0M
373 transactions
General
$104,282
732 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase II Trial of Daily LD IL-2 | Clinigen Inc | $2.3M | 0 |
| A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease | Prometheus Laboratories Inc. | $2.2M | 0 |
| A Phase I Study of Individual Adult and Pediatric Patient Dose-Escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease | Prometheus Laboratories Inc. | $2.0M | 0 |
| A Phase I Trial of Regulatory T-Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease | Prometheus Laboratories Inc. | $1.9M | 0 |
| Phase 2 Study of Adoptive Transfer of Autologous TIL in Patients with Metastatic Uveal Melanoma | Clinigen Inc | $1.9M | 0 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients with Metastatic Uveal Melanoma | Prometheus Laboratories Inc. | $1.6M | 0 |
| Phase II Trial of Daily LD IL-2 | Clinigen, Inc. | $1.5M | 0 |
| TIL multiple tumor types | Iovance Biotherapeutics, Inc. | $1.2M | 0 |
| Lymphodepletion +ACT Without Dendritic Cell Immunization | Clinigen Inc | $858,650 | 0 |
| Phase II Pembro + HD IL-2 for MM and RCC | Iovance Biotherapeutics, Inc. | $799,177 | 0 |
| Feasibility and Safety Investigation of ACT using TIL in multiple cancers | Clinigen Inc | $788,410 | 0 |
| Low Dose IL-2 for Treatment of Active Ulcerative Colitis | Prometheus Laboratories Inc. | $669,437 | 0 |
| TIL derived from NSCLC | Clinigen Inc | $655,740 | 0 |
| 10PLK13 - PROCLAIM Registry | Prometheus Laboratories Inc. | $586,655 | 0 |
| Lymphodepletion + Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients with Melanoma | Prometheus Laboratories Inc. | $585,587 | 0 |
| A Phase I Clinical Trial Combining Nivolumab and Adoptive Cell Therapy for Metastatic Non-small cell lung cancer | Prometheus Laboratories Inc. | $518,202 | 0 |
| Low Dose IL-2 for Ulcerative Colitis | Clinigen Inc | $515,130 | 0 |
| Phase 2 Study of Adoptive Transfer of Autologous TIL in Patients with Metastatic Uveal Melanoma | Clinigen, Inc. | $468,360 | 0 |
| Phase II LD IL-2 CGVHD | Iovance Biotherapeutics, Inc. | $444,128 | 0 |
| Phase II Trial of Extracorporeal Photophoresis (ECP) plus Low dose IL-2 for the treatment of Steroid Refractory Chronic Graft versus Host Disease (cGVHD) | Prometheus Laboratories Inc. | $440,803 | 0 |
Top Doctors Receiving Payments for Proleukin
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $32.1M | 385 |
| , MD | Medical Oncology | Portland, OR | $6,433 | 6 |
| , MD | Hematology & Oncology | Baton Rouge, LA | $5,554 | 4 |
| , MD | Medical Oncology | New Haven, CT | $5,339 | 3 |
| , MD | Medical Oncology | Indianapolis, IN | $4,725 | 2 |
| , M.D., PH.D | Hematology & Oncology | San Diego, CA | $4,200 | 2 |
| , MD | Hematology & Oncology | Maywood, IL | $3,056 | 5 |
| , MD | Hematology & Oncology | Boston, MA | $2,703 | 6 |
| , MD | Hematology & Oncology | Pittsburgh, PA | $2,469 | 4 |
| , M.D | Surgical Oncology | Chicago, IL | $2,165 | 8 |
| , MD | Internal Medicine | Tampa, FL | $2,136 | 2 |
| , M.D., PH.D | Medical Oncology | Baltimore, MD | $2,132 | 2 |
| , M.D | Medical Oncology | Boston, MA | $1,353 | 6 |
| , NP | Adult Health | Boston, MA | $1,000 | 1 |
| , MD | Internal Medicine | Indianapolis, IN | $638.68 | 7 |
| , MD | Internal Medicine | Duarte, CA | $603.36 | 5 |
| , MD | Medical Oncology | Nashville, TN | $603.36 | 5 |
| , MD | Hematology & Oncology | Boston, MA | $523.90 | 5 |
| , MD | Internal Medicine | Houston, TX | $514.11 | 4 |
| , MD MBBS | Medical Oncology | Buffalo, NY | $514.10 | 4 |
| , M.D | Medical Oncology | New Brunswick, NJ | $499.15 | 5 |
| Diwakar Davar | Hematology & Oncology | Pittsburgh, PA | $493.61 | 4 |
| , MD | Hematology & Oncology | Nashville, TN | $467.79 | 5 |
| , M.D | Medical Oncology | Tampa, FL | $457.99 | 4 |
| , MD | Specialist | Pittsburgh, PA | $420.89 | 6 |
Ad
Manufacturing Companies
- Prometheus Laboratories Inc. $14.9M
- Clinigen Inc $8.1M
- Iovance Biotherapeutics, Inc. $4.9M
- Clinigen, Inc. $4.3M
Product Information
- Type Drug
- Total Payments $32.1M
- Total Doctors 406
- Transactions 1,105
About Proleukin
Proleukin is a drug associated with $32.1M in payments to 406 healthcare providers, recorded across 1,105 transactions in the CMS Open Payments database. The primary manufacturer is Prometheus Laboratories Inc..
Payment data is available from 2017 to 2024. In 2024, $5.1M was paid across 51 transactions to 0 doctors.
The most common payment nature for Proleukin is "Unspecified" ($32.0M, 99.7% of total).
Proleukin is associated with 20 research studies, including "Phase II Trial of Daily LD IL-2" ($2.3M).